OptimizeRx Résultats passés
Passé contrôle des critères 3/6
Les bénéfices de OptimizeRx ont diminué à un taux annuel moyen de -22.6%, tandis que le secteur Healthcare Services a vu ses bénéfices augmenter de en à 19.5% par an. Les revenus ont augmenté de en à un taux moyen de 16.8% par an. Le rendement des capitaux propres de OptimizeRx est 4% et ses marges nettes sont de 4.7%.
Informations clés
-22.62%
Taux de croissance des bénéfices
-22.00%
Taux de croissance du BPA
| Healthcare Services Croissance de l'industrie | 1.72% |
| Taux de croissance des recettes | 16.77% |
| Rendement des fonds propres | 4.00% |
| Marge nette | 4.69% |
| Prochaine mise à jour des résultats | 12 May 2026 |
Mises à jour récentes des performances passées
Recent updates
OPRX: Share Repurchases And Margin Gains Will Support Future Upside Potential
The analyst price target for OptimizeRx has moved from $32 to $20 as analysts factor in softer 2026 revenue expectations, lower revenue growth assumptions, falling peer multiples, and a higher discount rate, partly offset by improved profit margin forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Recent research updates show that while price targets on OptimizeRx have been reset lower, several bullish analysts still highlight positive angles around execution, profitability, and capital allocation.
OPRX: Profit Execution And US$10m Buybacks Will Support Future Upside
Analysts have trimmed the blended price target for OptimizeRx to $14.50, reflecting softer 2026 revenue expectations, reduced revenue visibility, and lower peer multiples, partially offset by improved profit forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Street research on OptimizeRx has turned more cautious on the revenue outlook through 2026, but there is still a split between what bullish analysts focus on and what more bearish analysts are worried about.OPRX: Profit Focus And Buybacks Will Support Future Share Upside
Analysts have lowered their average price targets for OptimizeRx into the low to mid teens in dollar terms, citing reduced 2026 revenue visibility, softer pharma marketing budgets, pressure from peer multiples, and a greater focus on profitability and share repurchases. Analyst Commentary Street research on OptimizeRx has converged around lower price targets but with different degrees of optimism on execution, growth prospects, and valuation.OPRX: Margin Discipline And Buybacks Will Support Future Upside Potential
Analysts have reduced the fair value estimate for OptimizeRx from $24.33 to $14.50, citing lower revenue growth expectations, reduced revenue visibility into 2026, and lower peer P/E multiples. These factors are partly offset by firmer profit margin forecasts and buy ratings that remain in place across several firms.OPRX: Expanded Point Of Care Network Will Support Further Upside
Analysts have fine tuned their OptimizeRx price target to $24.33. This reflects updated assumptions around the discount rate, long term revenue growth, profit margin and future P/E multiple.
OPRX: New Data Partnerships Will Support Long Term Earnings Power
Analysts now maintain their price target for OptimizeRx at $17.00, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E that they view as broadly offsetting each other. What's in the News Announced a data collaboration with Experian at CES 2026 to connect OptimizeRx Micro-Neighborhood audiences with Experian's identity graph for onboarding, curation, and measurement of consumer audiences at scale (Client Announcements).OPRX: Q3 Outperformance And 2026 Guidance Will Strengthen Long Term Earnings Power
Analysts have lifted their average price targets on OptimizeRx into a US$21 to US$32 range, citing stronger than guided Q3 performance, improved visibility after 2024, and expectations for ongoing double digit growth with expanding margins. Analyst Commentary Street research after the Q3 report has centered on stronger than guided results and higher price targets, with analysts highlighting improved earnings and better visibility beyond 2024.OPRX: Q3 Execution Rebound And 2026 Guidance Will Support Further Upside
Analysts have lifted their blended price targets on OptimizeRx to a range of US$21 to US$32, citing stronger than guided Q3 revenue and EPS, improved visibility after 2024 execution issues, and continuing momentum that supports expectations for double digit growth with expanding margins. Analyst Commentary Across the Street, bullish analysts are taking Q3 as a sign that OptimizeRx may be getting back on track after earlier execution issues, and they have shifted their valuation ranges higher as a result.OPRX: Higher Guidance And Margin Expansion Will Reshape Long Term Earnings Power
Analysts have lifted their fair value estimate for OptimizeRx from US$11.00 to US$17.00, reflecting higher price targets supported by recent revenue and EPS outperformance, improved growth visibility, and expectations for margin expansion. Analyst Commentary Street research on OptimizeRx has been broadly positive around the latest quarter, with several firms raising their price targets after revenue and EPS outperformance and clearer guidance.OPRX Will Extend Double Digit Revenue Trajectory With New Multi Year Partnerships
Analysts have lifted their price target on OptimizeRx by $5 to $32 per share, citing consistently strong quarterly outperformance, improving visibility after last year's weak execution, and a more durable outlook for double digit revenue growth and expanding margins. Analyst Commentary Bullish analysts are increasingly aligned around a constructive view of OptimizeRx, pointing to a series of price target hikes following its latest quarterly results.OPRX: Recurring Revenue Shift And 2026 Guidance Will Drive Future Upside
Analysts have nudged their price targets on OptimizeRx higher, with recent increases across the Street ranging from about $1 to $10 per share to reflect stronger than expected Q3 revenue and EPS, improved visibility, and confidence in sustained double digit growth and margin expansion. Analyst Commentary Bullish analysts highlighted that the latest quarter materially exceeded revenue expectations, driving meaningful EPS upside and reinforcing confidence in a durable, double digit growth profile.OPRX: Multi-Year Guidance and Recurring Revenue Will Drive Upside Momentum
OptimizeRx's analyst price target has increased from $22 to approximately $24.33 per share. This reflects ongoing revenue outperformance and improved visibility that analysts attribute to strong quarterly results and the company's growing momentum.OptimizeRx Corporation's (NASDAQ:OPRX) 33% Share Price Plunge Could Signal Some Risk
Nov 23
OPRX: Expanding Margins and Subscription Model Will Drive Shareholder Value Forward
OptimizeRx's analyst fair value target has been raised from $19 to $22.00 per share. This change reflects stronger quarterly results, improved growth prospects, and expanding profit margins, according to analysts.Is OptimizeRx (NASDAQ:OPRX) Using Too Much Debt?
Oct 07Are Investors Undervaluing OptimizeRx Corporation (NASDAQ:OPRX) By 39%?
Aug 27Pharmaceutical Digital Engagement Will Unlock Future Value
Despite near-term cautious revenue guidance, analysts remain optimistic on OptimizeRx due to Q2 earnings outperformance, improved management transparency, and ongoing strategic initiatives, maintaining the consensus price target at $19.00. Analyst Commentary Bullish analysts highlight OptimizeRx’s Q2 revenues and adjusted EBITDA significantly surpassing forecasts.Even With A 33% Surge, Cautious Investors Are Not Rewarding OptimizeRx Corporation's (NASDAQ:OPRX) Performance Completely
May 09
A Subscription Model And EHR Network Will Reshape Healthcare
Transitioning to a subscription-based model aims to enhance revenue predictability and improve net margins with recurring income.Is OptimizeRx Corporation (NASDAQ:OPRX) Expensive For A Reason? A Look At Its Intrinsic Value
Apr 06We Think OptimizeRx (NASDAQ:OPRX) Has A Fair Chunk Of Debt
Mar 08At US$6.29, Is It Time To Put OptimizeRx Corporation (NASDAQ:OPRX) On Your Watch List?
Feb 14Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost
Dec 15Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?
Nov 16OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt
Jul 30OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors
Jan 09Ventilation des recettes et des dépenses
Comment OptimizeRx gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Dec 25 | 109 | 5 | 57 | 0 |
| 30 Sep 25 | 110 | 0 | 60 | 0 |
| 30 Jun 25 | 105 | -10 | 59 | 0 |
| 31 Mar 25 | 94 | -15 | 59 | 0 |
| 31 Dec 24 | 92 | -20 | 61 | 0 |
| 30 Sep 24 | 88 | -24 | 59 | 0 |
| 30 Jun 24 | 83 | -18 | 58 | 0 |
| 31 Mar 24 | 78 | -18 | 56 | 0 |
| 31 Dec 23 | 72 | -18 | 54 | 0 |
| 30 Sep 23 | 63 | -14 | 52 | 0 |
| 30 Jun 23 | 62 | -14 | 52 | 0 |
| 31 Mar 23 | 62 | -14 | 52 | 0 |
| 31 Dec 22 | 62 | -11 | 49 | 0 |
| 30 Sep 22 | 63 | -10 | 46 | 0 |
| 30 Jun 22 | 64 | -7 | 43 | 0 |
| 31 Mar 22 | 64 | -3 | 39 | 0 |
| 31 Dec 21 | 61 | 0 | 33 | 0 |
| 30 Sep 21 | 57 | 1 | 30 | 0 |
| 30 Jun 21 | 52 | 1 | 26 | 0 |
| 31 Mar 21 | 47 | -1 | 23 | 0 |
| 31 Dec 20 | 43 | -2 | 23 | 0 |
| 30 Sep 20 | 34 | -6 | 22 | 0 |
| 30 Jun 20 | 29 | -7 | 21 | 0 |
| 31 Mar 20 | 27 | -5 | 20 | 0 |
| 31 Dec 19 | 25 | -3 | 17 | 0 |
| 30 Sep 19 | 24 | -1 | 15 | 0 |
| 30 Jun 19 | 24 | 1 | 13 | 0 |
| 31 Mar 19 | 22 | 0 | 12 | 0 |
| 31 Dec 18 | 21 | 0 | 11 | 0 |
| 30 Sep 18 | 19 | 0 | 10 | 0 |
| 30 Jun 18 | 16 | -1 | 9 | 0 |
| 31 Mar 18 | 14 | -1 | 8 | 0 |
| 31 Dec 17 | 12 | -2 | 7 | 0 |
| 30 Sep 17 | 10 | -2 | 7 | 0 |
| 30 Jun 17 | 9 | -2 | 6 | 0 |
| 31 Mar 17 | 8 | -2 | 6 | 0 |
| 31 Dec 16 | 8 | -2 | 6 | 0 |
| 30 Sep 16 | 7 | -2 | 2 | 0 |
| 30 Jun 16 | 8 | -1 | 1 | 0 |
| 31 Mar 16 | 7 | -1 | 1 | 0 |
| 31 Dec 15 | 7 | -1 | 1 | 0 |
| 30 Sep 15 | 7 | 0 | 1 | 0 |
| 30 Jun 15 | 7 | 0 | 1 | 0 |
Des revenus de qualité: OPRX a des bénéfices de haute qualité.
Augmentation de la marge bénéficiaire: OPRX est devenu rentable dans le passé.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: OPRX est devenue rentable au cours des 5 dernières années, augmentant ses bénéfices de -22.6% par an.
Accélération de la croissance: OPRX est devenu rentable au cours de l'année dernière, ce qui rend le taux de croissance des bénéfices difficile à comparer à sa moyenne sur 5 ans.
Bénéfices par rapport au secteur d'activité: OPRX est devenue rentable au cours de l'année dernière, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Healthcare Services ( 27.3% ).
Rendement des fonds propres
ROE élevé: Le retour sur capitaux propres de OPRX ( 4% ) est considéré comme faible.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/05 22:19 |
| Cours de l'action en fin de journée | 2026/05/05 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
OptimizeRx Corporation est couverte par 12 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Anderson Schock | B. Riley Securities, Inc. |
| Constantine Davides | Citizens JMP Securities, LLC |
| Eric Martinuzzi | Lake Street Capital Markets, LLC |